Zevra Therapeutics (ZVRA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ZVRA Zevra Therapeutics

Watchlist

8.610
+0.370+4.49%

Trading Jan 8 13:37 ET

459.57MMarket Cap-4.04P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cantor Fitzgerald Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating, Announces Target Price $25
Moomoo NewsJan 8 07:34 ET · Ratings
Zevra Therapeutics (ZVRA) Receives a Buy From Cantor Fitzgerald
TipRanksJan 8 07:07 ET · Ratings
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long
Yahoo FinanceDec 27, 2024 05:26 ET
Top Picks for 2025 in Healthcare, Consumer, Tech, Industrials, Energy and More
Seeking AlphaDec 17, 2024 13:46 ET
Zevra Therapeutics to Be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
GlobeNewswireDec 17, 2024 07:30 ET
Zevra Therapeutics Restructures to Focus on Rare Diseases
TipRanksDec 6, 2024 17:48 ET

Comments

Trytosaveabit

Nov 21, 2024 16:02

Update

$Zevra Therapeutics (ZVRA.US)$ Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
GlobeNewswire· 7 mins ago
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra's specialty pharmacy for dispense
AmplifyAssist, Zevra's comprehensive patient support program, in place to address access barriers

Jaguar8

Nov 21, 2024 15:57

NEWS

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics (ZVRA) announces the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC). The medication is indicated for use with miglustat to treat neurological manifestations in patients 2 years and older. The company reports early adoption exceeding expectat...

Stock_Drift

Nov 11, 2024 15:42

$Zevra Therapeutics (ZVRA.US)$

Jaguar8

Nov 11, 2024 15:37

NEWS

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
Zevra Therapeutics (NASDAQ: ZVRA) announced the presentation of data validating the swallow domain's significance in the Niemann-Pick Disease Type C Clinical Severity Scale(NPCCSS) at the 53rd Child Neurology Society Annual Meeting. The study, presented by Dr. Elizabeth Berry-Kravis, in...

Meltyy

Sep 25, 2024 06:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

Heat List

Overall

No Data